Executive Interview – NeuroVive Pharmaceutical (Part 2)

Executive Interview – NeuroVive Pharmaceutical (Part 2)

NeuroVive is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT) and one project in clinical Phase I (KL1333) for genetic mitochondrial diseases. Here, CEO Erik Kinnman speaks about the progress KL1333 has made over the past month – receiving orphan drug designation in Europe and the status of the first clinical trial.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free